biotech
biotech Articles
Peregine Pharmaceuticals has announced that it is discontinuing its Phase 3 Sunrise trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell...
Published:
Last Updated:
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Published:
Last Updated:
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
Published:
Last Updated:
PTC Therapeutics said that it has received a Refuse to File letter from the FDA regarding its New Drug Application for Translarna (ataluren).
Published:
Last Updated:
Trevena charged after the FDA granted a Breakthrough Therapy designation to its lead product candidate for the management of acute pain.
Published:
Last Updated:
Allergan reported better-than-expected fourth-quarter financial results before the markets opened on Monday.
Published:
Last Updated:
Chimerix had a bad start to the week as it tumbled in early trading on Monday, following some late stage clinical trial results.
Published:
Last Updated:
Over the past week, Zafgen and a few other biotech companies made impressive runs. These moves were the result of positive trial results and an FDA meeting.
Published:
Last Updated:
Exagen Diagnostics has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Aerie Pharmaceuticals was one of the more bullish health care stocks on Thursday morning, following the release of its interim safety results.
Published:
Last Updated:
Zafgen has announced positive efficacy results from its Phase 2b ZAF-203 clinical trial evaluating beloranib, a MetAP2 inhibitor, in the treatment of severe obesity complicated by type 2 diabetes.
Published:
Last Updated:
Regulus Therapeutics has reported positive interim results from its Phase 2 study for the treatment of hepatitis C virus (HCV) infection.
Published:
Last Updated:
Ocular Therapeutix led the bulls in early trading indications on Thursday, following a positive meeting with the FDA.
Published:
Last Updated:
In 2016 alone, this stock has taken a beating, and unless this company can turn itself around in the near future, it could be the end.
Published:
Last Updated: